CIK 0001720580 · Non-accelerated filer<br>Smaller reporting company
Adicet Bio, Inc.
Sign in to watch- Ticker
- ACET
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 26
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813305277
- Phone
- 617-482-2333
- Business address
- 131 DARTMOUTH STREET, 3RD FLOOR, BOSTON, MA, 02116
- Former names
- resTORbio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-05 | Klickstein Lloyd Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +18,300 | 18,300 | ||
| 2026-06-21 | Peng Katie Director | Grant or award · Stock Option (Right to Buy) | +4,200 | 4,200 | ||
| 2026-06-21 | Klickstein Lloyd Director | Grant or award · Stock Option (Right to Buy) | +4,200 | 4,200 | ||
| 2026-06-21 | Sinclair Andrew Director | Grant or award · Stock Option (Right to Buy) | +4,200 | 4,200 | ||
| 2026-06-21 | Grissinger Michael Director | Grant or award · Stock Option (Right to Buy) | +4,200 | 4,200 | ||
| 2026-06-21 | Chodakewitz Jeffrey Director | Grant or award · Stock Option (Right to Buy) | +4,200 | 4,200 | ||
| 2026-06-21 | DUBIN STEVE Director | Grant or award · Stock Option (Right to Buy) | +4,200 | 4,200 | ||
| 2026-06-19 | Aftab Blake Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2026-06-19 | Schor Chen President & CEO | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other disposition | −250,000 | 932,624 | ||
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other acquisition · Pre-Funded Warrant (Right to Buy) | +250,000 | 1,402,833 | ||
| 2026-04-08 | ORBIMED ADVISORS LLC 10% owner | Sale | −32,523 | $6.29 | $205K | 0 |
| 2026-04-08 | ORBIMED ADVISORS LLC 10% owner | Sale | −40,416 | $6.52 | $264K | 0 |
| 2026-04-07 | ORBIMED ADVISORS LLC 10% owner | Sale | −29,319 | $6.53 | $191K | 34,923 |
| 2026-04-07 | ORBIMED ADVISORS LLC 10% owner | Sale | −2,400 | $6.38 | $15K | 32,523 |
| 2026-03-25 | Maltzman Julia D. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +72,555 | 72,555 | ||
| 2026-03-25 | Aftab Blake Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +72,555 | 72,555 | ||
| 2026-03-25 | Healey Don Chief Technology Officer | Grant or award · Stock Option (Right to Buy) | +43,361 | 43,361 | ||
| 2026-03-25 | Harvey Brian Nicholas Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +43,361 | 43,361 | ||
| 2026-03-25 | Schor Chen President & CEO | Grant or award · Stock Option (Right to Buy) | +468,555 | 468,555 |
Page 1 of 15 · 298 trades